Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery

Christopher P. Deibert; Manmeet S. Ahluwalia; Jason P. Sheehan; Michael J. Link; Toshinori Hasegawa; Shoji Yomo; Wu Han Feng; Pan Li; John C. Flickinger; L. Dade Lunsford; Douglas Kondziolka; Douglas Kondziolka

doi:10.1007/S11060-013-1214-3

Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery

Christopher P. Deibert, Manmeet S. Ahluwalia, Jason P. Sheehan, Michael J. Link, Toshinori Hasegawa, Shoji Yomo, Wu Han Feng, Pan Li, John C. Flickinger, L. Dade Lunsford, Douglas Kondziolka, Douglas Kondziolka

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	115
DOIs	https://doi.org/10.1007/S11060-013-1214-3
State	Published - Aug 9 2013

Disciplines

Medicine and Health Sciences
Neurology
Radiology

Access to Document

10.1007/S11060-013-1214-3License: Unspecified

Cite this

@article{9c82c73b974642b7997ca9db657009c0,

title = "Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery",

author = "Deibert, {Christopher P.} and Ahluwalia, {Manmeet S.} and Sheehan, {Jason P.} and Link, {Michael J.} and Toshinori Hasegawa and Shoji Yomo and Feng, {Wu Han} and Pan Li and Flickinger, {John C.} and Lunsford, {L. Dade} and Douglas Kondziolka and Douglas Kondziolka",

note = "To retrospectively evaluate the clinical benefit and imaging response of bevacizumab when used to treat refractory adverse radiation effects (ARE) after stereotactic radiosurgery. Twenty-nine patients with brain tumors or vascular malformations developed clinical and/or imaging evidence of ARE after SRS and were treated using bevacizumab.",

year = "2013",

month = aug,

day = "9",

doi = "10.1007/S11060-013-1214-3",

language = "American English",

volume = "115",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery

AU - Deibert, Christopher P.

AU - Ahluwalia, Manmeet S.

AU - Sheehan, Jason P.

AU - Link, Michael J.

AU - Hasegawa, Toshinori

AU - Yomo, Shoji

AU - Feng, Wu Han

AU - Li, Pan

AU - Flickinger, John C.

AU - Lunsford, L. Dade

AU - Kondziolka, Douglas

N1 - To retrospectively evaluate the clinical benefit and imaging response of bevacizumab when used to treat refractory adverse radiation effects (ARE) after stereotactic radiosurgery. Twenty-nine patients with brain tumors or vascular malformations developed clinical and/or imaging evidence of ARE after SRS and were treated using bevacizumab.

PY - 2013/8/9

Y1 - 2013/8/9

UR - http://europepmc.org/abstract/MED/23929592

U2 - 10.1007/S11060-013-1214-3

DO - 10.1007/S11060-013-1214-3

M3 - Article

VL - 115

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery

Disciplines

Access to Document

Other files and links

Cite this